OLMA Stock Forecast: Olema Oncology, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Olema Oncology, Inc. is $36. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 25 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Olema Oncology, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (60): The share price has been relatively steady.
Growth (17): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
OLMA stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on OLMA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Of the 20 most recent actions, 0 moved their price target up and 6 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 14 Sept 2026 | Stifel | Maintains | Buy | $48 → $30 |
| 13 Aug 2026 | JP Morgan | Maintains | Overweight | $52 → $46 |
| 11 Aug 2026 | Citigroup | Maintains | Buy | $62 → $59 |
| 11 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $38 → $36 |
| 13 May 2026 | Guggenheim | Maintains | Buy | $38 → $35 |
| 27 Mar 2026 | Wolfe Research | Initiates | Peer Perform | — |
| 19 Mar 2026 | Jefferies | Assumes | Buy | $43 → $40 |
| 18 Mar 2026 | Goldman Sachs | Maintains | Buy | — |
| 18 Mar 2026 | JP Morgan | Maintains | Overweight | — |
| 17 Mar 2026 | Citigroup | Maintains | Buy | — |
| 17 Mar 2026 | Guggenheim | Maintains | Buy | — |
| 9 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 11 Feb 2026 | Stifel | Initiates | Buy | — |
| 7 Jan 2026 | Piper Sandler | Initiates | Overweight | — |
| 7 Jan 2026 | UBS | Initiates | Buy | — |
| 12 Dec 2025 | Citigroup | Maintains | Buy | — |
| 11 Dec 2025 | Goldman Sachs | Maintains | Buy | — |
| 11 Dec 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 11 Dec 2025 | Oppenheimer | Maintains | Outperform | — |
| 21 Nov 2025 | Goldman Sachs | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for OLMA.
This page is one stock. Monday covers all of them.
OLMA appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
OLMA vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Olema Oncology, Inc. returned −68.1% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
OLMA analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 1.7×
- EV / EBITDA
- —
Cheaper than 50% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −69.8%
- Return on assets
- −39.8%
- Dividend yield
- —
Higher than 17% of US stocks
Higher than 10% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Olema Oncology, Inc. has a market value of $615.0M and an enterprise value of $204.6M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$204.6M.
Free cash flow in the twelve months to 30 June 2026: −$165.0M.
Olema Oncology, Inc. employs 131 people.
Data provided by Twelve Data
OLMA and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at OLMA’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Olema Oncology, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about OLMA
What is the OLMA stock price forecast for 2026-2027?
The median 12-month analyst price target for Olema Oncology, Inc. is $36, with estimates ranging from $13 to $59. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is OLMA stock a buy right now?
Of the 12 analysts covering Olema Oncology, Inc., 11 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Olema Oncology, Inc. 25 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank OLMA?
As at 21 Nov 2026, Olema Oncology, Inc. ranks 25 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Volatility (60 of 100).
Will OLMA stock go up?
No one can know that. What the data says: the median 12-month target from 12 analysts is $36, and Ticker Nerd's factor model ranks Olema Oncology, Inc. 25 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the OLMA stock forecast for 2030?
No analyst covering Olema Oncology, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OLMA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $13 to $59 over the next 12 months.
How has OLMA stock performed over the past year?
Olema Oncology, Inc. returned -68.1% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Olema Oncology, Inc. do?
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for women’s cancers, with a primary emphasis on breast cancer. The company’s current pipeline centers on palazestrant (OP-1250), an oral estrogen receptor antagonist and selective estrogen receptor degrader being studied for hormone receptor-positive breast cancer, and OP-3136, a KAT6 inhibitor in early clinical development.
About Olema Oncology, Inc.
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for women’s cancers, with a primary emphasis on breast cancer. The company’s current pipeline centers on palazestrant (OP-1250), an oral estrogen receptor antagonist and selective estrogen receptor degrader being studied for hormone receptor-positive breast cancer, and OP-3136, a KAT6 inhibitor in early clinical development. Olema’s research is built around endocrine-driven cancers and mechanisms of acquired resistance, reflecting a focus on precision oncology approaches for difficult-to-treat disease settings. The company is headquartered in San Francisco, California, with additional operations in Cambridge, Massachusetts. Olema Pharmaceuticals, Inc. plays a specialized role in the biotechnology market as a development-stage oncology company advancing novel medicines for breast cancer and related women’s cancers.
CEO Dr. Sean P. Bohen M.D., Ph.D. · 131 employees · United States · https://olema.com